Hot, hotter, and hottest trends in α-synuclein research

Current Protein and Peptide Science

Volumn 16, Issue 8, 2015, Pages 682-687

  Uversky, Vladimir N ^a,b,c,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c INSTITUTE OF CYTOLOGY   (Russian Federation)

^d INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PRION;

CLINICAL RESEARCH; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; MAMMAL CELL; MOLECULAR DYNAMICS; NERVE DEGENERATION; NOTE; NUCLEAR MAGNETIC RESONANCE; PROTEIN AGGREGATION; PROTEIN INTERACTION; CHEMISTRY; MEDICAL RESEARCH; METABOLISM; PATHOLOGY; PRION; PROTEINOSIS;

ALPHA-SYNUCLEIN; BIOMEDICAL RESEARCH; HUMANS; NERVE DEGENERATION; PRIONS; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84942112713     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920371608150828114357     Document Type: Note

References (69)

1. Olanow, C.W.; Tatton, W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 1999, 22, 123-144.
2. Moghal, S.; Rajput, A.H.; D'Arcy, C.; Rajput, R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology, 1994, 13(4), 175-178.
3. Fahn, S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci., 2003, 991, 1-14.
4. Forno, L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 1996, 55(3), 259-272.
5. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276(5321), 2045-2047.
6. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
7. Gomez-Tortosa, E.; Newell, K.; Irizarry, M.C.; Sanders, J.L.; Hyman, B.T. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. (Berl), 2000, 99(4), 352-357.
8. Spillantini, M.G.; Goedert, M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci., 2000, 920, 16-27.
9. Li, J.Y.; Henning Jensen, P.; Dahlstrom, A. Differential localization of alpha-, beta-and gamma-synucleins in the rat CNS. Neuroscience, 2002, 113(2), 463-478.
10. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 1995, 14(2), 467-475.
11. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T., Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35 (43), 13709-13715.
12. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 2001, 276(14), 10737-10744.
13. Li, J.; Uversky, V.N.; Fink, A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 2001, 40(38), 11604-11613.
14. Eliezer, D.; Kutluay, E.; Bussell, R., Jr.; Browne, G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol., 2001, 307(4), 1061-1073.
15. Uversky, V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn., 2003, 21(2), 211-234.
16. Fink, A.L. The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res., 2006, 39(9), 628-634.
17. Bartels, T.; Choi, J.G.; Selkoe, D.J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 2011, 477(7362), 107-110.
18. Wang, W.; Perovic, I.; Chittuluru, J.; Kaganovich, A.; Nguyen, L.T.; Liao, J.; Auclair, J.R.; Johnson, D.; Landeru, A.; Simorellis, A.K.; Ju, S.; Cookson, M.R.; Asturias, F.J.; Agar, J.N.; Webb, B.N.; Kang, C.; Ringe, D.; Petsko, G.A.; Pochapsky, T.C.; Hoang, Q.Q. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A., 2011, 108(43), 17797-17802.
19. Dettmer, U.; Newman, A.J.; Luth, E.S.; Bartels, T.; Selkoe, D. In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and betasynuclein in neurons and non-neural cells. J. Biol. Chem., 2013, 288(9), 6371-6385.
20. Fauvet, B.; Mbefo, M.K.; Fares, M.B.; Desobry, C.; Michael, S.; Ardah, M.T.; Tsika, E.; Coune, P.; Prudent, M.; Lion, N.; Eliezer, D.; Moore, D.J.; Schneider, B.; Aebischer, P.; El-Agnaf, O.M.; Masliah, E.; Lashuel, H.A. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem., 2012, 287(19), 15345-15364.
21. Binolfi, A.; Theillet, F.X.; Selenko, P. Bacterial in-cell NMR of human alpha-synuclein: a disordered monomer by nature? Biochem. Soc. Trans., 2012, 40(5), 950-954.
22. Coelho-Cerqueira, E.; Carmo-Goncalves, P.; Pinheiro, A.S.; Cortines, J.; Follmer, C. alpha-Synuclein as an intrinsically disordered monomer--fact or artefact? FEBS J., 2013, 280(19), 4915-4927.
23. Gurry, T.; Ullman, O.; Fisher, C.K.; Perovic, I.; Pochapsky, T.; Stultz, C.M. The dynamic structure of alpha-synuclein multimers. J. Am. Chem. Soc., 2013, 135(10), 3865-3872.
24. Selkoe, D.; Dettmer, U.; Luth, E.; Kim, N.; Newman, A.; Bartels, T. Defining the native state of alpha-synuclein. Neurodegener. Dis., 2014, 13(2-3), 114-117.
25. Luth, E.S.; Bartels, T.; Dettmer, U.; Kim, N.C.; Selkoe, D.J. Purification of alpha-Synuclein from Human Brain Reveals an Instability of Endogenous Multimers as the Protein Approaches Purity. Biochemistry, 2015, 54(2), 279-292.
26. Alderson, T.R.; Markley, J.L. Biophysical characterization of alpha-synuclein and its controversial structure. Intrinsically Disord. Proteins, 2013, 1(1), 18-39.
27. Deleersnijder, A.; Gerard, M.; Debyser, Z.; Baekelandt, V. The remarkable conformational plasticity of alpha-synuclein: blessing or curse? Trends Mol. Med., 2013, 19(6), 368-377.
28. Moriarty, G.M.; Janowska, M.K.; Kang, L.; Baum, J. Exploring the accessible conformations of N-terminal acetylated alpha-synuclein. FEBS Lett., 2013, 587(8), 1128-1138.
29. Berrocal, R.; Vasquez, V.; Krs, S.R.; Gadad, B.S.; Ks, R. alpha-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling. Mol. Neurobiol., 2015, 51(3), 1417-1431.
30. Kalia, L.V.; Kalia, S.K.; McLean, P.J.; Lozano, A.M.; Lang, A.E. alpha-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol., 2013, 73(2), 155-169.
31. Gautier, C.A.; Corti, O.; Brice, A. Mitochondrial dysfunctions in Parkinson's disease. Revue neurologique, 2014, 170(5), 339-343.
32. Bourdenx, M.; Bezard, E.; Dehay, B. Lysosomes and alpha-synuclein form a dangerous duet leading to neuronal cell death. Front. Neuroanat., 2014, 8, 83.
33. Winslow, A.R.; Rubinsztein, D.C. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy, 2011, 7(4), 429-431.
34. Lotharius, J.; Brundin, P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet., 2002, 11(20), 2395-2407.
35. Cheng, F.; Vivacqua, G.; Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat., 2011, 42(4), 242-248.
36. Picconi, B.; Piccoli, G.; Calabresi, P. Synaptic dysfunction in Parkinson's disease. Adv. Exp. Med. Biol., 2012, 970, 553-572.
37. Borza, L.R. A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases. Rev. Med. Chir. Soc. Med. Nat. Iasi., 2014, 118(1), 19-27.
38. Chua, C.E.; Tang, B.L. Rabs, SNAREs and alpha-synuclein--membrane trafficking defects in synucleinopathies. Brain Res. Rev., 2011, 67(1-2), 268-281.
39. Lazaro, D.F.; Rodrigues, E.F.; Langohr, R.; Shahpasandzadeh, H.; Ribeiro, T.; Guerreiro, P.; Gerhardt, E.; Krohnert, K.; Klucken, J.; Pereira, M.D.; Popova, B.; Kruse, N.; Mollenhauer, B.; Rizzoli, S.O.; Braus, G.H.; Danzer, K.M.; Outeiro, T.F. Systematic Comparison of the Effects of Alphasynuclein Mutations on Its Oligomerization and Aggregation. PLoS Genet., 2014, 10(11), e1004741.
40. Trojanowski, J.Q.; Lee, V.M. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci., 2003, 991, 107-110.
41. Dev, K.K.; Hofele, K.; Barbieri, S.; Buchman, V.L.; van der Putten, H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45(1), 14-44.
42. Uversky, V.N. Alpha-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci., 2008, 9(5), 507-540.
43. Uversky, V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem., 2007, 103(1), 17-37.
44. Chandra, S.; Gallardo, G.; Fernandez-Chacon, R.; Schluter, O.M.; Sudhof, T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 2005, 123(3), 383-396.
45. Jin, J.; Li, G. J.; Davis, J.; Zhu, D.; Wang, Y.; Pan, C.; Zhang, J. Identification of novel proteins interacting with both a-synuclein and DJ-1. Mol. Cell Proteomics, 2007, 6(5), 845-859.
46. Schnack, C.; Danzer, K.M.; Hengerer, B.; Gillardon, F. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. Neuroscience, 2008, 154(4), 1450-1457.
47. Lerner, A.; Bagic, A. Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov. Disord., 2008, 23(8), 1076-1084.
48. Visanji, N.P.; Brooks, P.L.; Hazrati, L.N.; Lang, A.E. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol. Commun., 2013, 1(1), 2.
49. Krammer, C.; Schatzl, H.M.; Vorberg, I. Prion-like propagation of cytosolic protein aggregates: insights from cell culture models. Prion, 2009, 3(4), 206-212.
50. Angot, E.; Brundin, P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15(Suppl 3), S143-147.
51. Cushman, M.; Johnson, B.S.; King, O.D.; Gitler, A.D.; Shorter, J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci., 2010, 123(Pt 8), 1191-1201.
52. Goedert, M.; Clavaguera, F.; Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci., 2010, 33(7), 317-325.
53. Lee, S.J.; Desplats, P.; Sigurdson, C.; Tsigelny, I.; Masliah, E. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol., 2010, 6(12), 702-706.
54. Dunning, C.J.; Reyes, J.F.; Steiner, J.A.; Brundin, P. Can Parkinson's disease pathology be propagated from one neuron to another? Prog. Neurobiol., 2012, 97(2), 205-219.
55. Hansen, C.; Li, J.Y. Beyond alpha-synuclein transfer: pathology propagation in Parkinson's disease. Trends Mol. Med., 2012, 18(5), 248-255.
56. Polymenidou, M.; Cleveland, D.W. Prion-like spread of protein aggregates in neurodegeneration. J. Exp. Med., 2012, 209(5), 889-893.
57. Yasuda, T.; Nakata, Y.; Mochizuki, H. alpha-Synuclein and neuronal cell death. Mol. Neurobiol., 2013, 47(2), 466-483.
58. Dunning, C.J.; George, S.; Brundin, P. What's to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease? Prion, 2013, 7(1), 92-97.
59. Olanow, C.W.; Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov. Disord., 2013, 28(1), 31-40.
60. Costanzo, M.; Zurzolo, C. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem. J., 2013, 452(1), 1-17.
61. George, S.; Rey, N.L.; Reichenbach, N.; Steiner, J.A.; Brundin, P. alpha-Synuclein: the long distance runner. Brain Pathol., 2013, 23(3), 350-357.
62. Narkiewicz, J.; Giachin, G.; Legname, G. In vitro aggregation assays for the characterization of alpha-synuclein prion-like properties. Prion, 2014, 8(1), 19-32.
63. Kovacs, G.G.; Breydo, L.; Green, R.; Kis, V.; Puska, G.; Lorincz, P.; Perju-Dumbrava, L.; Giera, R.; Pirker, W.; Lutz, M.; Lachmann, I.; Budka, H.; Uversky, V.N.; Molnar, K.; Laszlo, L. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol. Dis., 2014, 69, 76-92.
64. Angot, E.; Steiner, J.A.; Hansen, C.; Li, J.Y.; Brundin, P. Are synucleinopathies prion-like disorders? Lancet Neurol., 2010, 9(11), 1128-1138.
65. Mougenot, A.L.; Nicot, S.; Bencsik, A.; Morignat, E.; Verchere, J.; Lakhdar, L.; Legastelois, S.; Baron, T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging., 2012, 33(9), 2225-2228.
66. Betemps, D.; Verchere, J.; Brot, S.; Morignat, E.; Bousset, L.; Gaillard, D.; Lakhdar, L.; Melki, R.; Baron, T. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA. Acta Neuropathol. Commun., 2014, 2, 29.
67. Luk, K.C.; Kehm, V.M.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med., 2012, 209(5), 975-986.
68. Masuda-Suzukake, M.; Nonaka, T.; Hosokawa, M.; Oikawa, T.; Arai, T.; Akiyama, H.; Mann, D.M.; Hasegawa, M. Prion-like spreading of pathological alpha-synuclein in brain. Brain, 2013, 136(Pt 4), 1128-1138.
69. Reyes, J.F.; Rey, N.L.; Bousset, L.; Melki, R.; Brundin, P.; Angot, E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia, 2014, 62(3), 387-398.